Effect of pharmacological treatment on temperament and character in panic disorder.
Temperament and character were evaluated in patients with panic disorder (PD) before and after 1 year of pharmacological therapy to verify whether personality characteristics change after treatment. Therefore, 65 PD patients and 71 healthy subjects participated in the study. All subjects were evaluated with the SCID-IV, the Temperament and Character Inventory (TCI), the SCL-90, the Ham-A and the Ham-D. Patients were treated with paroxetine or citalopram. The TCI was re-administered to the patients at the end of the study. At the end of the study, complete remission was achieved by 31 patients (R), whereas symptoms did not disappear in the remaining 34 patients (NR). Before treatment, NR patients showed higher levels of harm avoidance (HA) and lower levels of persistence (P), self-directedness (SD) and cooperativeness (C) than healthy controls. Only HA levels were higher than normal in R, although they were significantly lower in R than in NR patients. These differences persisted after treatment. However, in NR patients the levels of SD and C worsened, whereas the difference between R patients and controls in HA levels (higher in R patients than in controls) disappeared after controlling the effect of residual phobic anxiety (higher than normal in R patients). Our data suggest that the high levels of HA found after remission may depend on the subsyndromal residual phobic symptoms, observed in R patients. Moreover, the persistence of anxious symptoms may have worsened the low levels of SD and C observed before treatment in patients who did not achieve remission.
Marchesi
Carlo
C
Department of Neuroscience, Psychiatric Section, University of Parma, Parma, Italy. carlo.marchesi@unipr.it
De Panfilis
Chiara
C
Cantoni
Alessandro
A
Giannelli
Maria R
MR
Maggini
Carlo
C
D000328:Adult; D001007:Anxiety / Q000517:prevention & control; D002605:Character; D015283:Citalopram / Q000494:pharmacology* / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D018757:GABA Modulators / Q000627:therapeutic use; D006801:Humans; D008140:Lorazepam / Q000627:therapeutic use; D008297:Male; D016584:Panic Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D017374:Paroxetine / Q000494:pharmacology* / Q000627:therapeutic use*; D010554:Personality Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control; D012074:Remission Induction; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013694:Temperament / Q000187:drug effects*
D015283:Citalopram; D018757:GABA Modulators; D008140:Lorazepam; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors